Related Experiment Video
Updated: Jun 17, 2026
14:04
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
VPAC receptor mediated tumor cell targeting by protamine based nanoparticles.
Anna Ortner1, Karin Wernig, Raphaela Kaisler
1Institute of Cancer Research, Medical University of Vienna, KIM-1, Vienna, Austria.
Journal of Drug Targeting
|January 7, 2010
Summary
Protamine-based nanoparticles (proticles) show promise for delivering vasoactive intestinal peptide (VIP) to tumors. These proticles protect VIP, enabling targeted delivery and internalization by cancer cells, suggesting potential for future clinical applications.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Vasoactive intestinal peptide (VIP) receptors (VPAC1, VPAC2, PAC1) are overexpressed on various tumor cells.
- VIP can target these receptors for drug delivery, but its short half-life limits efficacy.
- Enzymatic degradation of VIP hinders its therapeutic potential.
Purpose of the Study:
- To explore protamine-based nanoparticles (proticles) as a carrier for VIP-conjugated molecules.
- To evaluate the stability, targeting ability, and drug release of VIP-loaded proticles.
- To assess the potential of proticles for peptide-mediated tumor targeting.
Main Methods:
- Preparation and characterization of VIP-loaded proticles.
- Fluorescence Correlation Spectroscopy (FCS) for stability assessment.
- Confocal Laser Scanning Microscopy (CLSM) for cellular targeting and internalization studies.
- In vitro and ex vivo experiments using human tumors and rat tissue.
Main Results:
- VIP-loaded proticles demonstrated stability.
- Proticles specifically targeted tumor cells expressing VIP receptors.
- Cell binding triggered the release and internalization of VIP-Cy3 conjugates.
- VIP-releasing proticle depots were observed in rat tissue and human tumors.
Conclusions:
- Proticles effectively protect and deliver VIP for targeted tumor cell uptake.
- The proticle system facilitates VIP release and conjugate internalization.
- These findings support further investigation of proticles for in vivo and clinical peptide-mediated tumor targeting.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...